GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Encision Inc (OTCPK:ECIA) » Definitions » 3-Year RORE %

Encision (Encision) 3-Year RORE % : 149.06% (As of Dec. 2023)


View and export this data going back to 1996. Start your Free Trial

What is Encision 3-Year RORE %?

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Encision's 3-Year RORE % for the quarter that ended in Dec. 2023 was 149.06%.

The industry rank for Encision's 3-Year RORE % or its related term are showing as below:

ECIA's 3-Year RORE % is ranked better than
96.65% of 806 companies
in the Medical Devices & Instruments industry
Industry Median: -6.665 vs ECIA: 149.06

Encision 3-Year RORE % Historical Data

The historical data trend for Encision's 3-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Encision 3-Year RORE % Chart

Encision Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
3-Year RORE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -88.89 5,500.00 608.33 46.88 -426.32

Encision Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
3-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -426.32 -426.32 -631.58 -764.71 149.06

Competitive Comparison of Encision's 3-Year RORE %

For the Medical Instruments & Supplies subindustry, Encision's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Encision's 3-Year RORE % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Encision's 3-Year RORE % distribution charts can be found below:

* The bar in red indicates where Encision's 3-Year RORE % falls into.



Encision 3-Year RORE % Calculation

Encision's 3-Year RORE % for the quarter that ended in Dec. 2023 is calculated as:

3-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 3-year -Cumulative Dividends per Share for 3-year )
=( -0.041-0.038 )/( -0.053-0 )
=-0.079/-0.053
=149.06 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Dec. 2023 and 3-year before.


Encision  (OTCPK:ECIA) 3-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


Encision 3-Year RORE % Related Terms

Thank you for viewing the detailed overview of Encision's 3-Year RORE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Encision (Encision) Business Description

Traded in Other Exchanges
N/A
Address
6797 Winchester Circle, Boulder, CO, USA, 80301
Encision Inc is a medical device company. The company develops and markets technology that provides unprecedented outcomes and patient safety in minimally-invasive surgery. The company has established and developed AEM (Active Electrode Monitoring) technology and surgical instruments which provides surgeons with the desired tissue effects of cutting and coagulating tissue in laparoscopic procedures while preventing stray electrosurgical energy that can cause complications and even death. The segments of the company are Product and Service. Product designs develops, manufactures and markets patented surgical instruments. Service performs electrical engineering activities for external entities.
Executives
Robert H Fries director 800 FILLMORE ST, DENVER CO 80206
Peter D Geary officer: VP of Operations 6797 WINCHESTER CIRCLE, BOULDER CO 80301
Jason E Johnson officer: VP Sales 17752 WEDGEWOOD LANE, PRIOR LAKE MN 55372
Patrick R Dixon director 6797 WINCHESTER CIRCLE, BOULDER CO 80301
Gregory J. Trudel director, officer: CEO 5241 RIMROCK LANE, FORT COLLINS CO 80526
Brian J Jackman director 6797 WINCHESTER CIRCLE, SUITE 100, BOULDER CO 80301
Von Der Lippe Paul director 6797 WINCHESTER CIRCLE, BOULDER CO 80301
Denise Baker director 6797 WINCHESTER CIRCLE, BOULDER X1 80301
Vern D Kornelsen director, 10 percent owner 4605 S. DENICE DR, ENGLEWOOD CO 80111
Partners Lllp Cmed 10 percent owner
Patrick W Pace director 3701 SOARING EAGLE, AUSTIN TX 78746
Michael Biggs officer: VP Engineering 6797 WINCHESTER CIRCLE, BOULDER CO 80301
Brad Greathouse officer: VP RA/QA 6797 WINCHESTER CIRCLE, BOULDER CO 80301
Valerie Ray officer: VP of Operations 6797 WINCHESTER CIRCLE, BOULDER CO 80301
David W Newton director, officer: VP Technology 8099 NORTH 63RD STREET, LONGMONT CO 80503

Encision (Encision) Headlines